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Introduction
Whereas acute graft-versus-host disease (aGVHD)
rates have decreased with more intensive GVHD pre-
ventive agents and use of single and double umbilical
cord blood units as a source of donor cells in adult
recipients, significant chronic GVHD (cGVHD) rates
unexpectedly have remained high. Moreover, granulo-
cyte colony stimulating factor mobilized peripheral
blood stem cell grafts have been associated with an
increased overall risk of cGVHD. As such, cGVHD
has emerged as 1 of the primary causes of morbidity
andmortality following allogeneic hematopoietic stem
cell transplantation. Progress in developing cGVHD
interventional strategies has been hampered by variable
onset and clinical and pathological manifestations of
cGVHD, now better defined by theNational Institutes
ofHealth (NIH) consensus conference [1], and a dearth
of preclinical models that closely mimic the conditions
in which cGVHD is generated and manifested.
Although the exact causes of cGVHD remain un-
known, higher antibody levels have been associated
with autoimmunity and implicated in cGVHD [2,3].
Newly diagnosed patients with extensive cGVHD
had elevated soluble B cell activating factor levels and
anti-double-strand DNA antibodies were found [4,5],
which was associated with higher circulating levels
of pregerminal center (GC) B cells and post-GC
plasmablasts [6]. B cells from cGVHD patients were
hyperresponsive to Toll-like receptor-9 signaling and
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Existing cGVHD models simulate pathological
manifestations such as increased serum antibodies
(typically anti-DNA antibodies), scleroderma, and
fibrosis of skin and liver, and the less common immune
complex deposition in kidneys and glomerulonephritis
[8,9]. Previously, our laboratory has studied the
pulmonary dysfunction and aGVHD organ
pathology in mice conditioned with high-dose
cyclophosphamide (Cy) and lethal total body irradia-
tion and rescued with allogeneic bone marrow and
splenocytes [10]. The functional, physiologic, and
pathologic assays demonstrated that Cy and total
body irradiation conditioned recipients with low
numbers of allogeneic T cells developed bronchiolitis
obliterans (BO), characterized by airway blockade,
peribronchiolar fibroproliferation, and obliteration
of bronchioles [11,12]. BO is prevalent in 2% to 3%
of hematopoietic stem cell transplanation patients
and up to 6% of patients who develop GVHD [13],
and has a 5-year survival rate of only 10% [11]. Accord-
ing to the NIH consensus criteria [1], BO is the only
pathognomonic manifestation of pulmonary cGVHD.
By using a Cy and low doses of donor T cells,
aGVHD was avoided and cGVHD with BO favored.
Histologic changes were similar to the findings in
human cGVHD [2] with peribronchiolar and perivas-
cular cuffing and infiltration of the airway epithelium.
The liver had inflammation and lymphocytic infiltra-
tion, along with collagen deposition. The parotid
and submandibular salivary glands displayed lympho-
cytic infiltrates in both the bone marrow and cGVHD
groups, likely because of transplantation conditioning.
In the tongue, there was a quantifiable difference in the
histology and similar profiles of fibrosis seen in the
tongue and salivary glands for both groups. The
absence of any inflammatory or fibrotic changes in
the skin differs from some other models, reinforcing
the observation that in mice as in humans, the patho-
logic manifestations of cGVHD are heterogeneous.
Treatment of steroid refractory cGVHD patients
with rituximab, a B cell–depleting anti-CD20
monoclonal antibody, has shown a beneficial role in
resolution of the autoimmune disorders such as sys-
temic lupus erythmatosus and rheumatoid arthritis
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29% to 36% for oral, hepatic, gastrointestinal, and lung
cGVHD, and 60% for cutaneous cGVHD [19] in
aggregate data from multiple trials. Thus, we recently
undertook studies to identify the presence of CD41 T
helper cells and B2201 B cells in the airways of mice
that had BO, tissue-specific antibodies from sera, and
alloantibodydeposition in the lung and liver of cGVHD
recipients. cGVHD development was associated with
IgG2c deposition in the lung and liver, abrogated if
the donor bone marrow was deficient in mature B cells
or incapable of producing antihost reactive IgG.Robust
GC formation was seen in mice with cGVHD. Allevia-
tion of symptoms in mice that received B cell–deficient
bone marrow confirms the requirement of B cells for
lung dysfunction and inflammation and fibrosis in the
lung and liver.
Given a role for IgG antibodies, allo- or auto-Ab
binding to the cGVHD organs could enable tissue
destruction or the pathology could be defined by the
specific function of these secreted antibodies. Patho-
genic antibody production therefore is likely to be an
important inducer of cGVHD, and targeting this
specific function of the B cells is an attractive strategy
for cGVHD. Because GC B cells display lower suscep-
tibility to rituximab-mediated clearance, probably
because they reside in a nonoptimal environment for
antibody-based depletion [14], our observation that
GC B cells are critical to the development of cGVHD
suggests that agents that are more effective at disrupt-
ing the GCmight be more clinically useful. Treatment
with LTbR-Ig, a fusion protein that blocks interac-
tions between LTbR and its ligands, had a direct effect
on the symptoms of cGVHD, at least in part by
blocking GC formation and suggest that LTbR-Ig
could be a potential clinical interventional strategy
for prevention and therapy of cGVHD.TISSUE FIBROSIS: TOO MUCH OF A GOOD
THING?
Fibrosis is the end result of a number of inflamma-
tory and other injurious events, resulting in replace-
ment of normal tissue with a dense extracellular
matrix (ECM) scar composed primarily of collagens.
While some degree of tissue fibrosis is considered pro-
tective (e.g. in the setting of cutaneous wound healing),
exaggerated or unrelenting ECM deposition with re-
placement of the normal tissue architecture is consid-
ered pathologic. Fibroproliferative disorders as a class
involving multiple organs (e.g. cGVHD following he-
matopoietic stem cell transplant [affecting up to 30%
of recipients surviving more than 100 days [20]],
scleroderma [estimated to affect 70,000 in the US], id-
iopathic pulmonary fibrosis [estimated to affect
200,000 in the US], hepatic cirrhosis [estimated to af-
fect up to 400,000 in the US], and renal fibrosis due todiabetic nephropathy and other causes [estimated to
affect over 400,000 in the US]) are a major cause of
morbidity and mortality. Combined, these disorders
alone are conservatively estimated to affect approxi-
mately 1 in 300 persons in the United States. When
coupled with a host of other disorders in which tissue
fibrosis contributes to morbidity (e.g. fibroprolifera-
tive acute respiratory distress syndrome, hypersensitiv-
ity pneumonitis, solid organ transplant rejection), that
estimate is likely to be much greater. Extrapolated
globally (especially in developing countries where in-
fectious causes of fibrosis are quite prevalent), fibro-
proliferative disorders affect a large percentage of the
world population. Fibroproliferative diseases are often
difficult to treat, primarily because no therapeutic reg-
imens have been identified that will halt the relentless
tissue fibrosis. Thus, developing a better understand-
ing of tissue fibrogenesis is likely tomake a tremendous
impact in global health.
Wound healing occurs by a highly orchestrated,
complex process that has been well defined [21]. In
general, wound repair occurs in 4 stages which overlap
considerably: clotting/coagulation, inflammation, fi-
broproliferation, and tissue remodeling. The initial in-
jury leads to a local disruption of epithelial and
endothelial barriers resulting in the elaboration of in-
flammatory mediators and extravasation of cells and
plasma proteins that serve to achieve hemostasis and
provide a provisional fibrin-rich matrix for the influx
of inflammatory and other reparative cells [22]. Simul-
taneously, platelet degranulation provides a local
“boost” of vasodilators, growth factors, and ECM
proteins that aid in the wound healing response. In-
flammatory cell influx occurs next, with polymorpho-
nuclear leukocytes (PMNs) arriving first. Following
PMN degranulation, mononuclear cells (macrophages
and lymphocytes) arrive next and, along with PMN-
derived products, sterilize and remove foreign mate-
rials from the wound. This process also results in the
elaboration of cytokines and chemokines designed to
augment the inflammatory response, to promote an-
giogenesis (allowing for enhanced nutrient and oxygen
delivery to the wound bed), and to recruit fibroblasts to
the wound bed [22]. Fibroblast recruitment and
transdifferentiation to myofibroblasts (or recruitment
of already-differentiated myofibroblasts or fibroblast
precursors; this point is still controversial) marks the
fibroproliferative stage, with the result being the elab-
oration of ECM proteins (collagens, fibronectins) to
repair the tissue defect. As the fibroproliferative stage
matures, myofibroblasts contract the wound edges to
allow for efficient re-epithelialization. During the tis-
sue remodeling phase, myofibroblasts are induced to
undergo apoptosis, the neo-vessels regress, and the rel-
atively acellular scar tissue remains, ensuring tissue in-
tegrity. Following this overly simplified paradigm,
tissue fibrosis thus reflects a dysregulated wound
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along the way. Moreover, although tissue fibrosis re-
flects a ‘final common pathway’ after injury, significant
variations in tissue mechanics and ECM and cellular
specificity of tissues, it is highly likely that the patho-
genesis of fibrosis differs widely on an organ-specific
basis. Therefore, it is incumbent upon researchers to
investigate mechanisms of pathogenic fibrosis in rele-
vant organ systems and models.
Our lab has been interested in the role of the ECM
in initiating and propagating a fibrotic response. His-
torically, ECM deposition and subsequent remodeling
have been considered pathologic endpoints in tissue fi-
brosis. However, ECM remodeling is likely an itera-
tive process in which tissue responses to local injury
result in a cyclical process of ECM deposition, altered
ECM composition and mechanotransductive proper-
ties, release of locally-sequestered and newly-gener-
ated growth factors, cellular responses to ECM and
growth factors, and further ECM deposition and re-
modeling [23,24]. Cell behavior, largely influenced
by the ECM, dictates whether injury resolves
normally or results in progressive fibrosis. In the
lung, for example, the ECM strongly influences
alveolar re-epithelialization [25], epithelial-mesenchy-
mal transition (EMT) [26], fibroblast migration and
proliferation [27,28], fibroblast apoptosis [29], angio-
genesis [30] and ECM remodeling [31]. Thus, the
ECM is a significant contributor to tissue fibrosis.
With this background in mind, we sought to eval-
uate whether individual components of the ECM
might dictate fibrotic responses to injury. One such
ECM component, fibronectin, is a particularly attrac-
tive target based on data showing an absolute necessity
for fibronectin in development and wound repair [32].
Fibronectins are ubiquitous glycoproteins found in
plasma and in the ECM. The proteins consist of two
similar non-identical monomers, each roughly 250
kDa, which are joined by disulfide bonds at their
C-termini. Each monomer is composed of a series of
tightly folded homologous amino acid repeats or do-
mains, termed Type I, II, and III. Although arising
from a single gene, several variants of fibronectin are
formed by alternative splicing of the pre-mRNA at
three separate positions: the Extra Type III Domain
A (EDA) and Extra Type III Domain B (EDB), which
are each independently included or excluded [33], and
a V (for variable) region that undergoes more complex
splicing to produce 5 separate variants, resulting in up
to 20 potentially different fibronectin forms in humans
[34]. On the basis of solubility, however, fibronectin
can be divided into 2 forms - soluble plasma fibronec-
tin (pFn) and less-soluble or insoluble cellular fibro-
nectin (cFn) [35]. pFn is primarily synthesized by
hepatocytes and excludes the EDA and EDB domains
but retains variable V region splicing [34]. Conversely,
cFn is produced by epithelial and mesenchymal cellsand is characterized by the inclusion of EDA or EDB
(or both) in addition to the variable V region splicing
[32]. cFn is also stored in platelet -granules and is re-
leased following wounding by platelet degranulation
[36]. The EDA and EDB domains are typically incor-
porated into cFn in large quantities during embryonic
development and in malignancies, but at very low
levels or not at all in uninjured adult tissues [33].
Prior data suggested that EDA cFN is elaborated
in the lung of patients with idiopathic pulmonary fi-
brosis, a relentless fibrosing disorder of the lung that
has no known effective therapies [37]. Moreover, the
spatial location of EDA cFN, nestled between fibro-
blasts and collagen fibers within the lung [38], sug-
gested that EDA cFN may be present prior to
collagen deposition. Taking advantage of transgenic
animals lacking the EDA exon [39], our group sought
to evaluate the role of EDA cFN in lung fibrosis using
a standard bleomycin-induced lung fibrosis model.We
found that EDA-null mice failed to develop significant
fibrosis following bleomycin challenge as compared to
wild-type littermates, and that this, in part, may have
been due to impaired activation of the pro-fibrotic cy-
tokine TGF-b [31]. Similar results have been found in
EDA-deficient mice following myocardial infarction
[40], in an asthma model [41], and in the fibrosis of
chronic cardiac allograft rejection [42]. These data
suggest an active role of EDA cFN in tissue fibrosis.
Intriguingly, EDA cFN may also act as a plasma
biomarker of fibrotic diseases. Since EDA cFN is not
secreted into the circulation by hepatocytes [43], circu-
lating EDA cFN may reflect ongoing tissue remodel-
ing in fibrosing diseases. Supporting this hypothesis,
studies from several groups have documented an eleva-
tion of plasma EDA cFN in patients with cGVHD
[44], rheumatoid arthritis [45], and diabetes [46], as
well as in the plasma of mice with chronic rejection fol-
lowing cardiac transplantation [42]. Collectively, these
data suggest that ECM is an active contributor to tis-
sue fibrosis and may be a viable biomarker for fibrotic
diseases. Of course, further study is necessary to deter-
mine whether EDA cFN is a sensitive biomarker of
disease severity or progression, but these data suggest
that investigating the ECM in fibrotic diseases may
provide new insight into disease pathogenesis.CHRONIC GVHD: THE CLINICAL
PERSPECTIVE
Introduction
Chronic GVHD is a highly complex and polymor-
phic disease, with a largely unknown pathophysiology.
In the last decade, transplant clinicians became in-
creasingly aware that the traditional chronologic diag-
nostic criteria failed to address this complexity, and
that a substantial number of patients diagnosed with
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Most of these patients would transition, usually at
some point during the first year posttransplantation
into what we now consider cGVHD according to
NIH criteria. About a one-third of the cases of
cGVHDwill occur without a prior history of aGVHD.
Others will develop overlapping features of both
aGVHD and cGVHD for months or years. The vari-
ability of clinical presentations, from the patient with
a lichenoid form to the 1 that is immobile because of ad-
vanced sclerosis, demonstrates that cGVHD encom-
passes more than just 1 clinical syndrome.
Furthermore, the number of organs affected is different
and so far unpredictable for different patients. Finally,
depending on themanifestation of the disease, what we
see as clinicians may not be as clinically meaningful as
the patient-reported outcomes. Thus, depending on
our expectations, 1 perfect scoring system may not be
realistic.A Scoring System for cGVHD
The NIH Consensus was the first attempt to
resolve the diagnostic complexity of cGVHD, provid-
ing a clinical rather than chronologic framework, and
discriminating acute versus chronic manifestations
[1]. The NIH Consensus also produced a scoring and
assessment of response systems,mostly based on expert
opinion [1,20]. Both systems are based on a
combination of extensive description, as well as
objective and subjective measures. The relative
weight of each of these types of measures varies in
each organ, although this variation is still not based
on data correlating clinical descriptions with more
objective measures or outcomes. The objective is that
both the scoring and assessment of response systems
would provide more comprehensive prognostic and
evaluative measures. Different groups have focused
on prognosis, correlating the NIH Consensus scoring
system with different outcomes. Severe cGVHD
may impact survival, particularly when compared
with mild or no cGVHD [21-26]. Additionally, the
existence of an aGVHD component as late aGVHD
in the form of ‘‘overlap syndrome’’ may also confer
a poorer prognosis [21,23,26,27]. Severity of cGVHD
can also influence duration of immunosuppression
and recurrence of cGVHD. All of these findings need
to be confirmed prospectively, ideally with the
inclusion of patient-reported outcomes, which may
help to better characterize prognostic subsets [28,29].Common Problems in Diagnosis, Scoring, and
Follow-up
This section includes case presentations of chal-
lenging and not uncommon situations encountered
in clinical practice.Acute or chronic?
One of the major achievements of the NIH
Consensus has been the distinction between acute
and chronic clinical manifestations of cGVHD, inde-
pendent of chronology. This validated and formalized
the category of patents with ‘‘late’’ aGVHD, or
aGVHDbeyond day 100.Thus, a patient with diarrhea
secondary to aGVHDon day 99 posttransplantation, is
not reclassified as having cGVHD after day 100. The
question that remains is for how long a period of time
an aGVHDmanifestation should be considered acute.
In the absence of diagnosticmanifestations of cGVHD,
should diarrhea secondary to GVHD, which presents
years after transplantation, still be considered
aGVHD?Where would such patient fit in our current
scoring system?
Scoring GVHD of the lung
Chronic GVHD of the lung or BO is 1 of the most
difficult situations to diagnose and to score. Open lung
biopsies in transplant patients where the diagnosis is
suspected can be risky and difficult to justify outside
a clinical trial setting. Therefore, we generally rely
on a combination of clinical, spirometric, and radio-
logic findings with at least an additional distinctive
manifestation of cGVHD in another organ. Patients
with preexisting lung disease, infections, or those with-
out additional manifestations of cGVHD present
diagnostic and treatment challenges.
When severe becomes not so severe
The criteria for severity of cGVHD may not
always reflect our clinical impression. This is particu-
larly clear in certain organs and situations. A relatively
frequent and striking example is isolated severe ocular
cGVHD, where dryness can be almost completely
alleviated by special eyewear. In this case, cGVHD is
overall severe based on NIH Consensus criteria, inde-
pendent of the positive effects of intervention. Limited
sclerotic cGVHD of the skin without any functional
impact presents a similar challenge.
Disease activity and scoring system
How does our scoring system account for long-
term survivors with permanent sequelae of cGVHD,
without any major functional impact and off all immu-
nosuppression? In other words, at what point do we
stop scoring our patients for cGVHD?
Conclusions
The last decade has seen an explosion of interest in
the problems associated with survival after hematopoi-
etic stem cell transplantation, particularly cGVHD.
The NIH Consensus has provided for the first time
a systematic approach to a problem that we had recog-
nized as complex for years. This was also the starting
S188 Biol Blood Marrow Transplant 18:S184-S188, 2012B. Blazar et al.point of national and international collaborations,
interest groups, and other efforts directed to the com-
mon goal of improving the lives of our survivors. The
next step is to validate our starting point, assessing the
validity and reliability of our measurements, their abil-
ity to prognosticate, and to provide useful day-to-day
information on clinical changes. Because of the clinical
complexity of the disease, accurate assessment and
scoring will require the contribution of biomarker
and translational research.ACKNOWLEDGMENTS
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